Somaform's Neural Interface Faces Another Month Before the Regulators

The review has not concluded, and this week the regulators confirmed it will not conclude soon. Somaform Augmetics' neural-interface line remains under contested safety review, the same examination that has hung over the company all year, and the roughly five percent of humans now living with augmentation are watching a process with no announced end date. "I was cleared for my implant three years ago; my daughter is on a list that has not moved," said Rosa Villanueva, a Lisbon logistics worker whose family straddles the divide the review has frozen. Somaform founder Julian Morrow continues to argue that the technology is safe and the delay is the harm. Regulators counter that an open review is not a verdict but a duty. Neither the recall nor the clearance the two sides fear or hope for has come. For the augmented and the waiting alike, the interface's status this month is the one word no one finds tolerable: pending.